Mechanism of Action
Humanin exerts cytoprotection through multiple extracellular and intracellular signaling pathways.
JAK2/STAT3 Pathway
Humanin binds a heterotrimeric receptor complex composed of CNTFR, WSX-1, and gp130. This cytokine receptor trimer signals through JAK2 phosphorylation and STAT3 activation, driving anti-apoptotic gene transcription (Bcl-2, Bcl-xL) and neuronal survival. This pathway is the primary neuroprotective mechanism and is shared with CNTF (ciliary neurotrophic factor).[1]IGFBP-3 Binding and IGF-1 Modulation
Humanin binds IGFBP-3 (insulin-like growth factor binding protein 3), sequestering it and reducing IGFBP-3-mediated apoptosis. IGFBP-3 at high levels drives p53-dependent cell death, Humanin neutralizes this pathway. Simultaneously, Humanin binding may modulate IGF-1 bioavailability by displacing IGF-1 from IGFBP-3 complexes.[2]FPRL1 Receptor: Acute Anti-inflammatory Response
Humanin activates FPRL1 (formyl peptide receptor like-1), a G-protein coupled receptor on macrophages and dendritic cells. FPRL1 activation promotes resolution of inflammation and reduces oxidative burst in innate immune cells, contributing to Humanin's neuroprotective effects in inflammatory neurodegeneration models.[3]Research Overview
Alzheimer's Neuroprotection
Most StudiedHumanin was discovered specifically through its ability to prevent neuronal death from Alzheimer's disease-linked gene products (presenilin, amyloid precursor protein mutations). Consistent protection against beta-amyloid, ERAB/ABAD toxicity, and other AD-linked apoptosis triggers has been replicated across multiple labs and model systems.[1]
Aging Biomarker and Longevity
Strong EvidenceCirculating Humanin levels decline with age in humans, elderly (>70 years) have approximately 20-30% lower serum Humanin than young adults. Centenarian children have higher Humanin levels than age-matched controls, suggesting Humanin is positively associated with familial longevity. Animal studies show extended healthspan with Humanin supplementation.[4]
Metabolic Protection
Moderate EvidenceHumanin improves insulin sensitivity in diet-induced obesity models, reduces hepatic steatosis, and attenuates atherosclerotic plaque formation in APOE-knockout mice. Proposed mechanism involves STAT3-driven hepatic glucose regulation and anti-inflammatory effects in vascular endothelium.[2]
Reproductive and Testicular Protection
Moderate EvidenceHigh Humanin expression in testicular Sertoli cells protects male germ cells from apoptotic signals. Age-related decline in Humanin may contribute to male reproductive aging. Humanin supplementation preserved sperm count and quality in oxidative stress models.[3]
Calculate your Humanin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Neuroprotection / longevity | 2–5 mg | Once daily | Subcutaneous |
| Anti-aging mitochondrial stack | 5 mg Humanin + 10 mg MOTS-c + 1 mg SS-31 | Once daily | Subcutaneous (separate sites) |
| Conservative start | 2 mg | Once daily | Subcutaneous |
Morning dosing is standard. No meal timing requirement. Humanin is frequently included in comprehensive longevity peptide stacks alongside MOTS-c and SS-31 to provide complementary coverage of mitochondrial, metabolic, and cytoprotective aging mechanisms.
Research protocols only. Not medical advice.
Peptide Interactions
Safety Profile
Humanin has a favorable preclinical safety profile consistent with an endogenous protective peptide.
Endogenous peptide: Humanin is produced naturally by mitochondria and is present in human serum. No evidence of toxicity from restoration of declining age-related levels.
No significant adverse effects in animal studies: Multiple chronic dosing studies show no organ toxicity, behavioral changes, or hematological abnormalities at research doses.
IGFBP-3 interaction: Humanin's IGFBP-3 binding theoretically modulates IGF-1 bioavailability. The net effect is protective in most contexts, but monitoring is advisable when combining with exogenous IGF-1 protocols.
No FDA approval: Research compound. Phase I evaluation in Alzheimer's disease has been initiated. No approved therapeutic use.
References
- [1]Hashimoto Y, et al. "A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta." Proc Natl Acad Sci. 2001;98(11):6336-6341.
- [2]Muzumdar RH, et al. "Humanin: a novel central regulator of peripheral insulin action." PLoS One. 2009;4(7):e6334.
- [3]Gong Z, et al. "Humanin is an endogenous activator of chaperone-mediated autophagy." J Cell Biol. 2018;217(2):635-647.
- [4]Yen K, et al. "The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan." Aging (Albany NY). 2020;12(12):11185-11199.